Your Health, We Care
Avoid concomitant use of lazertinib with strong and moderate CYP3A4 inducers. Consider alternative concomitant medications that do not have CYP3A4-inducing potential.
Lazertinib is a substrate of CYP3A4. Concomitant use with strong or moderate CYP3A4 inducers will decrease lazertinib concentrations, which may reduce the efficacy of lazertinib.
Monitor for adverse reactions associated with CYP3A4 substrates as recommended in the approved product labeling of the CYP3A4 substrate, as small concentration changes may lead to serious adverse reactions.
Lazertinib is a weak CYP3A4 inhibitor. Concomitant use of lazertinib increases the concentrations of CYP3A4 substrates, which may increase the risk of adverse reactions related to these substrates.
Monitor for adverse reactions associated with BCRP substrates as recommended in the approved product labeling of the BCRP substrate, as small concentration changes may lead to serious adverse reactions.
Lazertinib is a BCRP inhibitor. Concomitant use of lazertinib increases the concentrations of BCRP substrates, which may increase the risk of adverse reactions related to these substrates.
FDA，2024.08
